IceCure Medical Appoints Medical Device Veteran Sharon Levita to its Board of Directors
Ms. Levita is a medical device veteran and brings extensive financial and business management experience in developing successful companies. Read more here
Meet IceCure at the largest radiology conference, RSNA, USA, Dec 2-4th, 2019
Schedule a meeting on Dec 2-4th with the IceCure Management, CEO, Eyal Shamir and VP Biz Dev & Marketing, Tlalit Bussi Tel Tzure at the Radiological Society of North America (RSNA) 2019, Dec 2-4th. Meet with us to learn the latest in our clinical research using the Prosense cryoablation system in interventional radiology. To confirm […]
Meet IceCure at leading medical device exhibition, MEDICA, Germany 2019
Schedule a meeting with our very own Biz Dev and Marketing Manager, Tlalit Bussi at MEDICA 2019. Join her to discuss potential new partnerships and learn more about how our LN2 cryoablation system, ProSense, is helping transform cancer treatment, without the need for surgery! To schedule a meeting, please email info@icecure-medical.com.
IceCure Medical Delivers Conference Call Investor Update Sept 2019
IceCure CEO, Eyal Shamir and CFO, Ronen Tsimerman update on IceCure progress in investor conference call, Sept 2019. Listen to the full conference call here.
IceCure Medical Forges Landmark Strategic Deal with Global Medical Company, Terumo Corporation
The exclusive distribution agreement, supported by Terumo’s strong commitment, will accelerate commercialization of its ProSense™ cryoablation system to treat breast cancer tumors in Japan and Singapore, pending regulatory approval. Read more
IceCure Receives Israeli AMAR Approval for Use of its Freezing Technology in Specific Indications, Following an Earlier General Approval
The AMAR approval allows for freezing of benign and malignant tumors including breast, lungs, bones, liver, lymphatic tissue, lymph nodes and endocrine glands. This achievement comes hot on the back of the company receiving a Class 3 CPT code from the American Medical Association that enables providers to apply for reimbursement for procedures using cryoablation […]
ICECURE TO CONDUCT HANDS-ON CRYOABLATION DEVICE TRAINING AT CIRSE 2019, SEPT 10, 12:30-14:00
Register now for our hands-on-device training at the Cardiovascular and Interventional Radiological Society of Europe annual conference on September 10th at 12:30-14:00. Come and learn more about how our next generation liquid nitrogen (LN2) cryoablation system, ProSense™, works to advance the treatment of kidney, lung and bone cancer without surgery. See you there!
ICECURE SUPPORTS THE FIRST-EVER BREAST CANCER LIQUID NITROGEN CRYOABLATION CONFERENCE, SEPT 20-21, 2019, KAMEDA MEDICAL CENTER
Led by leading expert, Professor Eisuke Fukuma, we are proud to support the first-ever breast cancer liquid nitrogen (LN2) cryoablation conference at Kameda Medical Center. Join this must-attend event to hear the latest clinical insights and results from leading doctors using ProSenseTM. Register today to reserve your spot (limited availability). Learn More
ICECURE PLATINUM SPONSOR OF THE 20TH WORLD CONGRESS OF THE INTERNATIONAL SOCIETY OF CRYOSURGERY, SEPT 4-5, 2019.
Demonstrating our commitment to advance the treatment of cancer using cryosurgery, we are proud to be the Platinum sponsor of the 20th World Congress of the International Society of Cryosurgery: Sept 4-5, 2019, Haifa, Israel. With talks from top experts sharing their latest clinical findings using our ProSense™ system, come and visit the IceCure booth […]
IceCure Medical Announces New Category III CPT Code for Breast Cryoablation Therapy, Issued by the American Medical Association
New Category III CPT Code expected to support further adoption of minimally invasive cryoablation treatments for breast cancer. Learn more.